Generic Name and Formulations:
Somatropin (rDNA origin) 4mg, 5mg, 6mg; per vial; for SC inj after reconstitution.
EMD Serono, Inc.
Indications for SEROSTIM:
HIV patients with wasting or cachexia to increase lean body mass and weight, and improve physical endurance.
Give by SC inj once daily at bedtime. Rotate inj sites. <35kg: 0.1mg/kg. 35–45kg: 4mg. 45–55kg: 5mg. >55kg: 6mg. Risk factors for adverse effects (eg, glucose intolerance): initially 0.1mg/kg every other day.
Not established; see full labeling.
Acute critical illness due to surgical complications or multiple accidental trauma or those with acute respiratory failure. Active malignancy. Active proliferative or severe non-proliferative diabetic retinopathy.
Increased mortality in those with acute critical illness (see Contraindications). Use only under guidance of a physician trained in HIV management. HIV patients should be maintained on antiretroviral therapy. Glucose intolerance. Diabetes. Perform baseline and periodic funduscopic evaluation for intracranial hypertension; discontinue if papilledema occurs; may restart at lower dose after resolution. Monitor for development, progression, or recurrence of neoplasms. Discontinue if carpal tunnel syndrome persists after dosage reduction. Turner syndrome. Elderly. Pregnancy (Cat.B). Nursing mothers.
May be antagonized by glucocorticoids. May affect CYP450 substrates (eg, corticosteroids, sex steroids, anticonvulsants, cyclosporine); monitor. Concomitant oral estrogens; may require larger somatropin doses. Concomitant insulin and/or hypoglycemics may require dose adjustment.
Growth hormone (GH).
Musculoskeletal discomfort, increased tissue turgor, edema, nausea, fatigue, gynecomastia, paresthesia, hypoesthesia, hyperglycemia, hypertriglyceridemia, carpal tunnel syndrome; intracranial hypertension, serious hypersensitivity reactions; rare: pancreatitis.
Single-dose vials (5mg, 6mg)—7 (w. diluent); Multi-dose vials (4mg)—7 (w. diluent)
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Obesity, Male Gender May Improve Survival Outcomes with Targeted and Immunotherapy in Melanoma
- Apalutamide Prolongs Time to Metastasis in Castration-resistant Prostate Cancer
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
- Zinc Sulfate Improves Chemotherapy-Induced Mucositis Outcomes in Leukemia
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Travel Distance to Prostate Cancer Treatment Influences Treatment Choice
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|